A total of 277 revision surgeries have been performed due to the faulty ASR hip implants manufactured by DePuy International Ltd, a subsidiary of Johnson and Johnson, Minister of State for Health Ashwini Choubey told the Rajya Sabha Tuesday.
The minister was replying to a question on whether faulty hip implants had resulted in deaths and disability of several patients.
"As per the information available with the Central Drugs Standard Control Organisation (CDSCO), 277 revision surgeries were undertaken because of disability due to faulty Articular Surface Replacement (ASR) hip implants manufactured by M/s DePuy International Limited, UK, (now M/s Johnson & Johnson Pvt Ltd)," Choubey said in his reply.
He said the government had set up a panel to examine issues relating to the faulty hip implants. The committee, after a detailed examination of the issue, submitted its report to the government, which accepted the recommendations with some modifications.
Based on the accepted recommendations, the government constituted a central expert committee under the chairmanship of Sports Injury Centre Director RK Arya inter-alia to determine the quantum of compensation, Choubey said.
The Health Ministry has also requested all the states/UTs to form state-level committees to examine the affected patients within their jurisdiction so that the process is less arduous for them.
"A formula for determining compensation for the affected patients has also been formulated and placed in public domain. The affected patients can approach either the central expert committee or state-level committee as per their convenience," Choubey said.
Responding to a question on whether the government was aware that the hip implants of the same manufacturer were recalled in the United States due to its faulty equipments and if so, the reasons it was allowed to market the product in India, Choubey said the product was recalled in the US in August 2010.
In India, the firm recalled it on August 24, 2010 and Central Drugs Standard Control Organisation (CDSCO) acknowledged their recall and no further import of the product was allowed, he said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)